My name is Marc Lichtenfeld.
I’m Senior Healthcare Analyst for The Oxford Club.
As a financial analyst, I’ve been written up in publications including The Wall Street Journal, and The Street.com, where I was a Senior Columnist.
Marketocracy – a leading research company that evaluates the investment industry – shows one of my model portfolios outperformed 99% of those tracked on their site based on 5-year performance.
I’ve spent the vast majority of my working days the past 15 years researching high-return opportunities in the biotech, healthcare and technology markets…
And my research has made some folks very large amounts of money, as you’ll see below.
How is that possible?
Of course it has a lot to do with my tens of thousands of hours of due diligence… and years of experience in the markets.
But it’s also thanks to the valuable time I spend talking with drug company executives, pharma industry insiders and hedge fund managers.
This kind of personal interaction can yield “advantages” not available to just about anyone else out there. For example…
I doubt these kinds of gains would have been possible without my in-the-trenches investigation and analysis.
Numerous major investment firms and professionals rely on my research, as well, including…
But I’m most proud of the tremendous returns I’ve brought to readers in the recent past.
Yet I believe the opportunities from this coming $4-trillion healthcare explosion stand to eclipse – by far – even my most successful prior recommendations.
Here are three specific opportunities I’m researching right now that could hand you a fortune in the coming months.